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The enteropathogenic and enterohemorrhagic Escherichia coli NleB proteins as well as
the Salmonella enterica SseK proteins are type III secretion system effectors that function
as glycosyltransferase enzymes to post-translationally modify host substrates on arginine
residues. This modification is unusual because it occurs on the guanidinium groups of
arginines, which are poor nucleophiles, and is distinct from the activity of the mammalian
O-linked N-acetylglucosaminyltransferase. We conducted high-throughput screening
assays to identify small molecules that inhibit NleB/SseK activity. Two compounds,
100066N and 102644N, both significantly inhibited NleB1, SseK1, and SseK2 activities.
Addition of these compounds to cultured mammalian cells was sufficient to inhibit
NleB1 glycosylation of the tumor necrosis factor receptor type 1-associated DEATH
domain protein. These compounds were also capable of inhibiting Salmonella enterica
strain ATCC 14028 replication in mouse macrophage-like cells. Neither inhibitor was
significantly toxic to mammalian cells, nor showed in vitro cross-reactivity with the
mammalian O-linked N-acetylglucosaminyltransferase. These compounds or derivatives
generated frommedicinal chemistry refinements may have utility as a potential alternative
therapeutic strategy to antibiotics or as reagents to further the study of bacterial
glycosyltransferases.
Keywords: bacterial pathogenesis, glycosylteransferase, innate immnuity, signal transduction, virulence, type III
secreted effector protein
INTRODUCTION
Many Gram-negative bacterial pathogens interact with mammalian cells by using a specialized type
III secretion system (T3SS) to inject proteins directly into infected host cells (Notti and Stebbins,
2016; Deng et al., 2017). A subset of these injected protein “effectors” are enzymes that modify the
structure and function of human proteins by catalyzing the addition of unusual post-translational
modifications (Ribet and Cossart, 2010; Salomon and Orth, 2013). Some T3SS effectors play
important roles in bacterial virulence andmay be “druggable” targets for anti-virulence compounds
that could be used to replace or augment traditional antibiotic regimens (Kimura et al., 2011;
Warrener et al., 2014; Gu et al., 2015; McShan and De Guzman, 2015).
The NleB1/NleB2 (enteropathogenic and enterohemorrhagic E. coli; EPEC and EHEC) and
SseK1/SseK2/SseK3 (Salmonella enterica) T3SS effectors are glycosyltransferases that modify
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protein substrates on arginine residues (Li et al., 2013; Pearson
et al., 2013). This modification is unusual because it occurs
on the guanidinium groups of arginines, which are poor
nucleophiles. This modification is biologically important because
the glycosylation of arginines on protein substrates disrupts the
normal functioning of the innate immune system (Li et al., 2013;
Pearson et al., 2013; El Qaidi et al., 2017). Several death domain-
containing proteins have been described as substrates of some
of the NleB/SseK orthologs, including the Fas-associated protein
with death domain (FADD), tumor necrosis factor receptor
type 1-associated DEATH domain protein (TRADD), and the
receptor-interacting serine/threonine-protein kinase 1 (RIPK1)
(Li et al., 2013). Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (Gao et al., 2013) and hypoxia-inducible factor 1-
alpha (HIF1α) (Xu et al., 2018) are additional substrates. Recent
structural characterization of a subset of the NleB/SseK orthologs
revealed that these proteins are retaining glycosyltransferases
consisting of three functional domains, namely a helix-loop-helix
(HLH) domain, a lid domain, and a catalytic domain with a
HEN motif (His-Glu-Asn) that is required for catalytic activity
(Esposito et al., 2018; Park et al., 2018).
NleB1 is a signature of EHEC strains that have been observed
to cause widespread foodborne outbreaks that develop into cases
of hemolytic uremic syndrome (HUS) (Wickham et al., 2006).
HUS, which is caused by the activity of a Shiga-like toxin, leads to
destruction of the endothelial cells of the kidney and is often fatal
(Loos et al., 2018). Antibiotic therapy against EHEC is typically
contraindicated, because antibiotics may induce increased Shiga-
like toxin expression, exacerbating patient symptoms (Wong
et al., 2000). This motivated our work, which sought to identify
small molecule inhibitors of NleB1 as a potential alternative
therapeutic strategy to antibiotics. Such compounds may also be
of utility asmechanistic probes for understanding themechanism
of the NleB/SseK effector family.
RESULTS
NleB1 Inhibitor Screening
Wedeveloped and optimized a high-throughput screening (HTS)
assay for NleB1 inhibitors. Purified, recombinant forms of wild-
type E. coli O157:H7 NleB1 (Figure 1A) and, as a negative
control, an inactive form of NleB1 (NleB1-AAA) in which
the aspartic acid residues required for Mn2+ stabilization were
mutated to alanines, were produced (Gao et al., 2013). We
then optimized the conditions in which these enzymes could be
studied in a solution-based assay that produces a luminescent
signal when UDP-GlcNAc is hydrolyzed by NleB1 to liberate
UDP (Figure 1B).
Optimal NleB1 activity was observed at 0–25mM NaCl and
10mM MgCl2, with >50% loss of activity at 500mM NaCl and
at 50mM MgCl2. NleB1 activity increased linearly up to 2 h and
no loss of activity was observed up to 4% DMSO. The kinetic
parameters of NleB1 (150 nM at 30◦C) were calculated as follows:
Vmax: 2,975.3 ± 125 RLU/min/µg protein; Km: 379 ± 43µM;
Kcat (s-1): 50, Kcat/Km (s-1, M-1): 130,703.4. As expected,
the NleB1-AAA mutant enzyme had no detectable activity (not
shown).
FIGURE 1 | HTS assay. (A) SDS-PAGE analysis of the recombinant proteins
used in this study. (B) UDP liberation (RLU/min) is plotted as a function of
substrate (UDP-GlcNAc) concentration in the presence of NleB1. (C)
Summary of HTS assay data. The % inhibition of UDP liberation is plotted as a
function of the well number of each compound represented in the CMLD
library of 5,160 compounds. Compounds (n = 52) that inhibited the assay to
>3 standard deviations ± the plate median were identified as positive hits.
We then screened the University of Kansas Center of
Excellence in Chemical Methodologies and Library Development
(KU CMLD, https://cmld.ku.edu/outreach) library of 5,160
compounds. This library utilizes new principles of scaffold
design, incorporates multiple scaffold cores into a single library,
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and contains compounds that are likely to have pharmacological
activity based on sound drug design principles. The structures




An average Z′ Score of 0.88 ± 0.05 was obtained across all 15
plate assays in the pilot screen for NleB1 inhibitors (Figure 1C).
Compounds were tested in a concentration dose-response (10–
160µM) assay. Of all the compounds that inhibited the primary
assay at single concentration, 80% of the hits inhibited NleB1 in
a dose-responsive manner. Compounds (n = 52) that inhibited
NleB1to >3 standard deviations ± plate median were scored
as hits in the assay (hit rate of 1%; Supplemental Table 1).
The two most potent compounds (100066N and 102644N) were
resynthesized as fresh powders for further study (Figure 2A).
100066N is a flavone analog that has been previously synthesized
(Ahn et al., 2007). 102644N is a substituted isoxazole whose
synthesis has also been described (Waldo et al., 2008). Compound
104108N, which was not identified as a hit in our HTS assay, was
used as a negative control in some subsequent experiments.
In vitro Glycosylation Assays
We performed secondary screens to evaluate the ability of these
compounds to inhibit NleB1 and SseK1 glycosylation of the
human GAPDH protein substrate (Gao et al., 2013, 2016; El
Qaidi et al., 2017). 100066N and 102644N were both active
against both NleB1 and SseK1 (Figures 2B,C). We corroborated
these data by quantifying UDP liberation in a UDP-Glo assay
as a function of inhibitor concentration. Both 100066N and
102644N inhibited NleB1 activity in a concentration dependent
manner, whereas compound 104108N, the negative control, did
not inhibit NleB1 (Figure 2D). SseK2 glycosylates the human
FADDprotein (El Qaidi et al., 2017).We also tested the inhibitory
effect of 100066N and 102644N on SseK2 and found that these
compounds both inhibited FADD glycosylation by SseK2 in a
concentration-dependent manner (Figure 2E).
Cell Culture Assays
NleB1 glycosylates human TRADD on R235, thereby blocking
death domain interactions and disrupting tumor necrosis
factor signaling (Li et al., 2013). We next assessed whether
100066N and/or 102644N would be effective in inhibiting
NleB1 activity in mammalian cells. We co-transfected HEK293
cells with NleB1 and TRADD expression plasmids in the
presence or absence of these compounds and then performed
immunoblotting assays to measure TRADD glycosylation. We
observed that both compounds, when provided at 1µM
concentration to HEK293T cells, were effective in reducing
the extent of TRADD glycosylation by NleB1 (Figure 3A).
Neither inhibitor was significantly toxic to mammalian cells,
as inferred from performing 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assays as a function of
inhibitor concentration (Figure 3B).
The human O-linked N-acetylglucosaminyltransferase
(OGT) is an essential serine/threonine N-acetylglucosamine
(O-GlcNAc) transferase that maintains protein glycosylation
homeostasis (Zhao et al., 2018). Deletion of OGT is lethal
and deficiencies in OGT activity are associated with
neurodegenerative diseases and gut inflammation (Zheng
et al., 2016; Zhao et al., 2018). To consider the future use of
100066N and 102644N as potential therapeutics, we next tested
whether they also inhibit OGT. Neither 100066N nor 102644N
inhibited the activity of a recombinant form of human OGT
(Figure 3C). These data suggest that the two NleB1 inhibitors
we initially characterized are specific to the pathogen enzymes
that glycosylate arginine residues, rather than cross-react with
the mammalian OGT enzyme that glycosylates Ser/Thr residues
(Aquino-Gil et al., 2017).
Neither 100066N nor 102644N directly impacted the growth
rates of E. coliO157:H7 and Salmonella entericawhen supplied at
500µM concentrations in bacterial cultures (Figure 3D). These
data suggest that the inhibitors specifically target the NleB/SseK
virulence factors, rather than act as general bacteriostatic or
bactericidal agents.
Finally, we quantified the impact of these inhibitors on
Salmonella replication in RAW264.7 cells. When 102644N
and 100066N (1 or 10µM) were added to RAW264.7 cells
prior to their infection with WT Salmonella, we observed that
both inhibitors (at 10µM) significantly reduced the number
of WT Salmonella 24 h after infection (Figure 3E, top). We
performed similar experiments with Salmonella 1sseK2sseK3
(expressing only SseK1) and observed that both inhibitors at
both 1 and 10µM further reduced the replication of Salmonella
1sseK2sseK3 (Figure 3E, middle). We also assessed the impact
of 102644N and 100066N on Salmonella 1sseK1sseK2sseK3 and
found there was no further impact of these inhibitors on the
already relatively-low abundance of this triple-mutant strain
(Figure 3E, bottom).
DISCUSSION
The T3SS and its effectors are of critical importance to the
virulence of many Gram-negative pathogens (Gaytan et al.,
2016). Bacterial virulence is significantly decreased in T3SS-
deficient strains, whereas bacterial replication is not typically
affected (Nordfelth et al., 2005). Thus, chemicals targeting the
T3SS or its effectors are appealing, as they are less likely to be
subject to evolutionary pressures toward resistance (Gu et al.,
2015; McShan and De Guzman, 2015).
We screened for and identified two small molecules, 100066N
and 102644N, that are effective in inhibiting the activities of
NleB1, SseK1, and SseK2. We used a relatively small compound
library for these initial studies and it is likely that future HTS
assays using larger compound libraries may reveal more effective
compounds. It is notable that although our primary screen was
designed to target only the EHEC NleB1 protein, both 100066N
and 102644N showed activity against not only NleB1, but also
SseK1 and SseK2.
It was promising to note that neither 100066N nor 102644N
were toxic to mammalian cells, nor did they directly affect E.
coli or Salmonella growth. Given the significant difference in the
NleB/SseK mechanism of action as compared to OGT, it was
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FIGURE 2 | In vitro glycosylation assays. (A) 100066N, 102644N, and 104108N structures. (B) Western blot analysis of the inhibition of NleB1 and SseK1
glycosylation of GAPDH by 100066N and 102644N. (C) Quantification of panel B, n =3. (D) UDP-Glo assays were performed using 250 nM NleB1, in 125mM Tris pH
7.4, 25mM MnCl2, 2.5mM DTT, and 100µM UDP-GlcNAc in the presence of inhibitor concentrations ranging from 1nM to 500µM. (E) Western blot analysis of the
inhibition of SseK2 glycosylation of FADD by 100066N and 102644N.
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FIGURE 3 | Cellular assays. (A) Western blot analysis of the inhibition of NleB1
glycosylation of TRADD by 100066N and 102644N in HEK293T cells. (B) MTT
assays. Quantification of normalized MTT signal intensities as a function of
100066N and 102644N concentrations added to HEK293T cells for 24 h. (C)
OGT assays. OGT was incubated with a recombinant OGT-peptide substrate
in the presence of 100066N and 102644N and then subjected to
immunoblotting using an anti-O-GlcNAc monoclonal antibody. (D) Bacterial
growth assays. EHEC (left) and Salmonella (right) were cultured in the
presence of the indicated compounds and growth was monitored as a
function of time. (E) 100066N and 102644N reduce Salmonella replication in
macrophages. Inhibitors (1 or 10µM) were added to RAW 264.7 cells for 1 h
prior to infection with 106 CFUs of the indicated Salmonella strains. Colony
counts were enumerated 24 h later. Asterisks indicate a significant difference (p
< 0.05) from samples lacking inhibitors, as determined using one-way analysis
of variance (ANOVA) with Dunnett’s multiple comparisons tests.
reassuring but perhaps not surprising to observe that neither
inhibitor affected theO-linked glycosylation of anOGT substrate.
We also noted that neither 100066N nor 102644N further
impacted the colonization of the Salmonella 1sseK1sseK2sseK3
triple mutant, suggesting few significant off-target effects of these
compounds.
The extent to which the SseK enzymes are redundant
and/or are important to survival in mouse macrophages is
still unclear and some of our data are in contrast to previous
studies. Initially it was concluded that effects of SseK1 and
SseK2 are not evident in infections of RAW 264.7 cells in
a comparison of single- and double-mutants with wild-type
serovar Typhimurium SL1344 (Kujat Choy et al., 2004). Later
it was realized that this strain also expresses SseK3 and these
experiments were reassessed (Brown et al., 2011). While no
phenotype was observed in RAW 264.7 cells, it was shown that a
1sseK1sseK2 double mutant was attenuated in competitive index
infections of mice (Brown et al., 2011). Our experiments instead
used Salmonella enterica ATCC 14028 and thus our observation
that both 1sseK1sseK2 and 1sseK1sseK2sseK3 were attenuated
in macrophages in comparison to the wild-type strain may be
due to strain-dependent differences. We also failed to observe
significant macrophage death in our studies.
Although a structure is available in the Protein Data Bank
(PDB) for SseK3 [6EYR; (Esposito et al., 2018)], the lack of
confirmed substrates for this effector limited our ability to
assess the efficacy of 100066N and 102644N against SseK3. We
previously characterized the structures of NleB2 (5H5Y), SseK1
(5H60), and SseK2 (5H61, 5H62, 5H63) (Park et al., 2018).
We are currently attempting to generate co-crystal structures
between SseK1 and 100066N and 102644N both to understand
how these compounds inhibit these glycosyltransferases and to
identify the residues they bind in the enzymes. We speculate that
100066N and 102644N could affect UDP-GlcNAc binding and/or
hydrolysis, activation of the acceptor arginine, or affect the
flexibility of the HLH domain which we have attributed to being
important to the recognition of the acceptor protein substrates
containing death domains (Park et al., 2018). Future approaches
to study the efficacy of these inhibitors will also include
derivatization of both 100066N and 102644N. Logical medicinal
chemistry strategies include the exploration of substitution effects
on the furan and phenyl moieties at the 3 and 5 positions of
102644N as well as bioisosteric replacement of the sulfonamide
linker and determining the effect of substituents on phenyl ring
for 100066N.
EXPERIMENTAL PROCEDURES
Cloning and Cell Lines
The plasmids used in this study are listed in Table 1.
Human embryonic kidney 293 cells (HEK 293) and Abelson
murine leukemia virus induced, macrophage-like cells from
BALB/c mice (RAW264.7) were purchased from ATCC.
Both cell lines were grown in DMEM (Thermo Scientific),
supplemented with 10% FBS (Atlanta Biologicals) and 100µg/ml
penicillin/streptomycin (Sigma) in 5% CO2. nleB1 (EHEC
EDL933), sseK1, and sseK2 (Salmonella enterica ATCC 14028)
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TABLE 1 | Plasmids used in this study.
Description Source
GST-EHEC-NleB1 El Qaidi et al., 2017
GST-EHEC-NleB1(AAA) Gao et al., 2013
GST-SseK1 El Qaidi et al., 2017
GST-SseK2 El Qaidi et al., 2017
HA-EHEC-NleB1 Gao et al., 2013
His-FADD El Qaidi et al., 2017
His-GAPDH Gao et al., 2013
His-OGT This study
His-OGT substrate (KKKYPGGSTPVSSANMM)-GAPDH This study
TRADD-FLAG This study
were cloned into pET42a. A human OGT substrate peptide
(KKKYPGGSTPVSSANMM) was fused to the N-terminus
of GAPDH and expressed in pET28a. Human FADD was
expressed in pET15a. Plasmids were transformed into E.
coli BL21 (DE3). Protein overexpression was performed for
4 h at 37◦C upon induction with 0.5mM IPTG. His-tagged
proteins were purified using nickel agarose beads (Qiagen)
as described previously (El Qaidi et al., 2017). Salmonella
mutants were constructed using lambda red recombination
(Datsenko and Wanner, 2000).
Protein Purification
E. coli BL21 (DE3) strains harboring protein expression plasmids
were grown at 37◦C in LB containing 50µg/ml kanamycin
until an OD600 of 0.4, at which time 0.5mM IPTG was
added for 4 h further growth. Cells were harvested using
centrifugation and the pellet was resuspended in 1/40 culture
volume of lysis buffer (50mM sodium phosphate NaH2PO4
pH 8.0, 0.5 mg/ml lysozyme). The suspension was incubated
on ice for 30min with occasional shaking and then an equal
volume of 50mM sodium phosphate pH 8.0, 2M NaCl, 8mM
imidazole, 20% glycerol, 2% Triton X-100, was added for an
additional 30min of incubation. Cell lysates were sonicated,
centrifuged, and then the resultant supernatant was added
to 2ml Ni-NTA resin (Qiagen) for 1 h of rotation at 4◦C.
The mixture was loaded on a Poly-Prep Chromatography
Column (Bio-Rad) and washed with 10ml of 50mM sodium
phosphate pH 8.0, 600mM NaCl, 60mM imidazole, 10%
glycerol. Proteins were eluted in 2ml 50mM sodium phosphate
pH 8.0, 600mM NaCl, 250mM imidazole, 10% glycerol and
dialyzed into the same buffer lacking imidazole overnight at
4◦C. We note that some of the proteins appeared to show
cleavage of the epitope tag after purification and other proteins
formed higher molecular weight aggregates when resolved using
SDS-PAGE.
HTS Assay Optimization
The glycosyltransferase activity of NleB1 was tested using
the luminescence based UDP-GloTM Glycosyltransferase Assay
(Promega) according to the manufacturer’s instructions. The
optimized assay was performed by incubating purified NleB1
(150 nM) with UDP-GlcNAc (300µM) for 2 h at 30◦C, followed
by the addition of UDP detection reagent to covert UDP to
ATP, which is then utilized by luciferase to generate light
in proportion to the UDP concentration. The luminescence
was read using a BioTek Synergy Neo (BioTek Inc.). The
assay was optimized for buffer components (MgCl2, NaCl),
linearity of the assay, the concentration ranges of NleB1 and
UDP-GlcNAc, optimal temperature, and the Km of NleB1 for
UDP-GlcNAc.
Pilot Library Screening
The optimized assay was used to screen a KU Legacy
collection of 5,160 diversity compounds synthesized by The
Chemical Methodologies and Library Development (CMLD)
Center. Assays were performed in buffer containing 50mM
Tris pH 7.5, 100mM NaCl, 1mM DTT, 10mM MgCl2
and 0.5% DMSO. NleB1 (150 nM) was pre-incubated for
30min in 384 well-microplates, containing CMLD compounds
(20µM) transferred acoustically using ECHO555 (Labcyte Inc).
Luminescence was read 2 h after the addition of the UDP
detection reagent. Each screening plate contained 16 wells of
minimum signal (no enzyme, substrate only in 0.5% DMSO,
for average and standard deviation calculations, SD min)
and 16 wells of maximum signal (enzyme + 0.5% DMSO
+ Substrate, for average and standard deviation calculations,
max). The distribution of controls across each plate was
used to calculate Z′ scores, using the equation z′ = (1 −
3SDmin+3SDmax
Average max−Average min ). The percent inhibition was normalized
to the controls and compounds that inhibited the assay to >3
standard deviations plus the plate median were identified as
hits.
Glycosylation Assays
In vitro glycosylation assays were performed as described
previously (El Qaidi et al., 2017). Briefly, 200 nM of enzyme
(NleB1, SseK1, or SseK2) was incubated with 1µM of GAPDH
or FADD in the presence or absence of the studied inhibitors in
buffer containing 50mM Tris-HCl pH 7.4, 1mM UDP-GlcNAc,
10mM MnCl2, and 1mM DTT. After 2 h incubation at RT,
samples were subjected to western blotting using an anti-R-
GlcNAc monoclonal antibody (Abcam). Assays with OGT were
performed in buffer containing 25mM Tris-HCl pH 7.4, 1mM
UDP-GlcNAc, 12.5mM MgCl2, and 1mM DTT. After 4 h of
incubation at RT, samples were subjected to western blotting
using an anti-O-GlcNAc monoclonal antibody (Millipore).
Signal intensities were quantified using Li-COR Image Studio
software and inhibition was calculated by quantifying the relative
reduction in substrate glycosylation after normalization to the
effect of DMSO.
UDP-Glo Assays
UDP-Glo luminescence assays were performed in
96 well-microplates, containing 250 nM NleB1 in
125mM Tris pH 7.4, 25mM MnCl2, 2.5mM DTT,
and 100µM UDP-GlcNAc in the presence of inhibitor
concentrations ranging from 1 nM to 500µM. Reactions
were incubated for 2 h at 30◦C and then developed and
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quantified using a FLUOstar microplate reader (BMG
Labtech).
Transfections
HEK293T cells were co-transfected with NleB1-HA and
TRADD-FLAG plasmids in the presence or the absence of
inhibitors. At 24 h post-transfection, cells were washed with
PBS, suspended in SDS sample buffer, boiled for 10min, and
immunoblotted with an anti-R-GlcNAc monoclonal antibody
(Abcam).
MTT Assays
MTT assays were performed as specified by Millipore using HEK
293 cells in the presence of 2-fold serial dilutions of 100066N or
102644N. Formazan absorbance was measured using an Epoch
Microplate Spectrophotometer (BioTek).
Macrophage Infections
Macrophage infection assays were performed to measure the
intracellular invasion of bacteria in the presence of 100066N
or 102644N. RAW264.7 cells were seeded at 1 x 105 cells/well
in 24-well plates and inhibitors were added at 1 or 10µM
final concentrations 1 h before infection. Bacterial cultures were
grown overnight and 106 CFUs were added to each well
for 30min. Cells were then incubated in medium containing
100µg/mL gentamicin for 1 h, and then 10µg/mL gentamicin for
an additional 23 h. Bacteria were released from RAW264.7 cells
using 1% saponin, diluted in PBS, and plated for colony counts.
Statistical Analyses
Data were analyzed statistically using one-way analysis of
variance (ANOVA) with Dunnett’s multiple comparisons tests.
P-values < 0.05 were considered significant.
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